NCT03669601 - AZD6738 & Gemcitabine as Combination Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2024

Conditions

Cancer

Interventions

DRUG

AZD6738

A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.

DRUG

Gemcitabine

Nucleoside metabolic inhibitor.

Trial Locations (1)

CB2 2QQ

RECRUITING

Cambridge University Hospitals NHS Foundation Trust, Cambridge